Trending >

ADVERTISE WITH CANTECH

NANALYSIS $160-MILLION CONTRACT

CUBICFARMS FINANCING

NEXTECH AR UP 12.5%

author

Geordie Carragher

Geordie Carragher is a staff writer for Cantech Letter

The Latest From Geordie Carragher

Analysts Cannabis DNA

Ginkgo Bioworks is looking attractive, says Raymond James

Analysts Cannabis ffnt

4Front Ventures is a Buy in US cannabis, says Haywood

Analysts quis

It’s time to buy Quisitive Technology Solutions, says Beacon

Analysts Health hls

HLS Therapeutics is practically a double from here, says Clarus

Analysts Marketing Media bbtv

Huge runway to BBTV, says Scotiabank

Analysts Hardware bln

Blackline Safety keeps Buy rating with PI Financial

Analysts Health slhg

Skylight Health has target reduced by Echelon

Analysts Cannabis xly

Auxly Cannabis has 135 per cent upside, says Raymond James

Analysts Cannabis flwr

Take a pass on The Flowr Corp, says ATB

Analysts Marketing wish

Wishpond Technologies keeps bullish $3 target with Paradigm Capital

Analysts Cannabis ndva

Indiva keeps Outperform rating with Raymond James

Analysts Health ops

OpSens is now very undervalued, says Raymond James

Analysts Gaming pmkr

Playmaker Capital is a screaming buy, says Echelon

Analysts Cannabis jush

Jushi has a 275 per cent runway, says ATB

Analysts ata

ATS Automation is heading north of $60, says Stifel

Analysts Health qipt

Quipt Home Medical is a double, says Raymond James

Analysts Resource Tech gra

NanoXplore receives a target drop from Beacon

Analysts IT cts

Converge Technology should hit $11.00, says Laurentian

Analysts Marketing dcm

Still more upside to DATA Communications, says Clarus

Analysts Health exe

Extendicare downgraded by Leede Jones Gable

Analysts Software ksi

kneat.com keeps Buy rating with Echelon

Analysts Cannabis cchw

Columbia Care has target trimmed by Echelon

Analysts Health drdr

MCI Onehealth keeps Buy rating with Echelon

Analysts Marketing at

AcuityAds gets a target cut from Echelon

Analysts Health slhg

Skylight Health is still a pass, says Raymond James

Analysts Cleantech Resource Tech grn

Greenlane Renewables still a Buy, says Beacon

Analysts Fintech mogo

Mogo sees a big target cut from Eight Capital

Analysts Automotive exro

Exro Technologies is a Buy, says Haywood

pmn

ProMIS Neurosciences gets coverage launch from Leede Jones Gable

Analysts Health lspk

LifeSpeak selloff uncalled for, says Desjardins

Share

Tweet

Share

Get Stock Picks from the Pros. In your Inbox.